Substance / Medication

Aldesleukin

Overview

Active Ingredient
aldesleukin
RxNorm CUI
70223
Labeler: Iovance Biotherapeutics, IncUpdated: 2024-12-20T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Dosage and Administration (2.4) Contraindications (4) Warnings and Precautions (5.1) [see,,] Capillary leak syndrome (CLS), including life threatening or fatal reactions, has occurred in patients treated with Proleukin. Do not administer Proleukin to patients with significant cardiac, pulmonary, ren

Contraindications

When this intervention should not be used

Severe Hypersensitivity Reactions Organ Allografts Significant Organ Impairment Adverse Reactions (6.2) [see]. Proleukin is contraindicated in patients with a known history of severe hypersensitivity to aldesleukin or any component of the Proleukin formulation Warnings and Precautions (5.5) [see] Pr

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report.
Anastasopoulou Amalia, Gkoufa Aikaterini, Diamantopoulos Panagiotis et al. · Immunotherapy · 2022
PMID: 35852114Case ReportFull text (PMC)
Dantrolene sodium for the treatment of aldesleukin-induced rigors in a melanoma patient.
Azari Laleh M, Sheehan Vivien S, Sachdev Jasgit C et al. · Ann Pharmacother · 2012
PMID: 22510667Case Report
Pseudosystemic sclerosis as a complication of recombinant human interleukin 2 (aldesleukin) therapy.
Marie I, Joly P, Courville P et al. · Br J Dermatol · 2007
PMID: 17199595Case Report
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
Gogas Helen, Ravimohan Shruthi, Datta Antara et al. · NPJ Precis Oncol · 2024
PMID: 39025948OtherFull text (PMC)
Immuno-inflammatoryhepatotoxicity models to assess side effects of biologicals exemplified by aldesleukin.
Roser Luise A, Luckhardt Sonja, Ziegler Nicole et al. · Front Immunol · 2023
PMID: 38045689OtherFull text (PMC)
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Siefker-Radtke Arlene O, Huddart Robert A, Bilen Mehmet A et al. · Urol Oncol · 2025
PMID: 39477771Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Aldesleukin (substance)
SNOMED CT
386917000
UMLS CUI
C0218986
RxNorm CUI
70223
Labeler
Iovance Biotherapeutics, Inc

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

6
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.